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For treating multidrug-resistant tuberculosis (MDR TB), the World Health Organization
(WHO) recommends a regimen of at least four second-line drugs that are likely to be effec-
tive as well as pyrazinamide. WHO guidelines indicate only marginal benefit for regimens
based directly on drug susceptibility testing (DST) results. Recent evidence from isolated
cohorts suggests that regimens containing more drugs may be beneficial, and that DST
results are predictive of regimen effectiveness. The objective of our study was to gain
insight into how regimen design affects treatment response by analyzing the association
between time to sputum culture conversion and both the number of potentially effective
drugs included in a regimen and the DST results of the drugs in the regimen.
Methods and Findings
We analyzed data from the Preserving Effective Tuberculosis Treatment Study (PETTS), a
prospective observational study of 1,659 adults treated for MDR TB during 2005–2010 in
nine countries: Estonia, Latvia, Peru, Philippines, Russian Federation, South Africa, South
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Korea, Thailand, and Taiwan. For all patients, monthly sputum samples were collected, and
DST was performed on baseline isolates at the US Centers for Disease Control and Preven-
tion. We included 1,137 patients in our analysis based on their having known baseline DST
results for at least fluoroquinolones and second-line injectable drugs, and not having exten-
sively drug-resistant TB. These patients were followed for a median of 20 mo (interquartile
range 16–23 mo) after MDR TB treatment initiation. The primary outcome of interest was ini-
tial sputum culture conversion. We used Cox proportional hazards regression, stratifying by
country to control for setting-associated confounders, and adjusting for the number of drugs
to which patients’ baseline isolates were resistant, baseline resistance pattern, previous
treatment history, sputum smear result, and extent of disease on chest radiograph.
In multivariable analysis, receiving an average of at least six potentially effective drugs
(defined as drugs without a DST result indicating resistance) per day was associated with a
36% greater likelihood of sputum culture conversion than receiving an average of at least
five but fewer than six potentially effective drugs per day (adjusted hazard ratio [aHR] 1.36,
95% CI 1.09–1.69). Inclusion of pyrazinamide (aHR 2.00, 95% CI 1.65–2.41) or more drugs
to which baseline DST indicated susceptibility (aHR 1.65, 95% CI 1.48–1.84, per drug) in
regimens was associated with greater increases in the likelihood of sputum culture conver-
sion than including more drugs to which baseline DST indicated resistance (aHR 1.33, 95%
CI 1.18–1.51, per drug). Including in the regimen more drugs for which DST was not per-
formed was beneficial only if a minimum of three effective drugs was present in the regimen
(aHR 1.39, 95% CI 1.09–1.76, per drug when three effective drugs present in regimen).
The main limitation of this analysis is that it is based on observational data, not a random-
ized trial, and drug regimens varied across sites. However, PETTS was a uniquely large and
rigorous observational study in terms of both the number of patients enrolled and the stan-
dardization of laboratory testing. Other limitations include the assumption of equivalent effi-
cacy across drugs in a category, incomplete data on adherence, and the fact that the
analysis considers only initial sputum culture conversion, not reversion or long-term relapse.
Conclusions
MDR TB regimens including more potentially effective drugs than the minimum of five cur-
rently recommended byWHOmay encourage improved response to treatment in patients
with MDR TB. Rapid access to high-quality DST results could facilitate the design of more
effective individualized regimens. Randomized controlled trials are necessary to confirm
whether individualized regimens with more than five drugs can indeed achieve better cure
rates than current recommended regimens.
Introduction
World Health Organization (WHO) guidelines for the treatment of multidrug-resistant tuber-
culosis (MDR TB) recommend a regimen consisting of at least four second-line drugs that are
likely to be effective as well as pyrazinamide [1]. In the absence of drug susceptibility testing
(DST) results for a patient’s isolate, likely effectiveness is determined based on previous expo-
sure to a drug, background resistance levels to that drug in the community, and, in patients
who were contacts to other known cases, DST results for an associated case. Furthermore, the
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guidelines indicate that only marginal benefit has been observed for regimens based directly on
the DST results for a patient’s isolate [1].
A meta-analysis of cohort studies of patients with MDR TB reported that in vitro suscepti-
bility to individual drugs was consistently and statistically significantly associated with higher
odds of treatment success compared to in vitro resistance, suggesting clinical utility for DST in
regimen design [2]. In addition, the use of baseline DST results to design individualized regi-
mens involving prolonged use of five or more drugs with likely effectiveness has been associ-
ated with decreased risks of treatment failure, death, and relapse among patient cohorts in
Peru and the Russian Federation [3–5]. Together, this evidence suggests the need to reassess
both the role of DST in regimen design as well as the potential benefit of including more drugs
in MDR TB regimens.
To gain insight into how regimen design affects treatment response, we analyzed treatment
and microbiological data from the Preserving Effective Tuberculosis Treatment Study
(PETTS), a 6-y, multinational prospective cohort study of patients with MDR TB [6]. As our
goal was to focus on the association between DST results and the direct microbiological effect
of drugs, we used time to sputum culture conversion as an indicator of the bactericidal effect of
treatment. We assessed the association between the number of potentially effective drugs
included in a regimen and time to sputum culture conversion. In addition, we compared the
individual effects of drugs to which DST results indicated susceptibility, drugs to which DST
results indicated resistance, and drugs that were not tested.
Methods
Ethics
PETTS was approved by the US Centers for Disease Control and Prevention (CDC) Institu-
tional Review Board and institutional review boards at all participating sites. Written informed
consent was obtained from all study participants.
Patient Population and Study Procedures
The PETTS study design and patient population have been described previously [6]. Briefly,
this prospective cohort study, conducted in 2005–2010, enrolled consecutive adults with pul-
monary MDR TB in nine countries: Estonia (nationwide), Latvia (nationwide), Peru (two dis-
tricts in Lima), Philippines (greater Manila), Russian Federation (Orel and Vladimir Oblasts),
South Africa (Eastern Cape, KwaZulu-Natal, Mpumalanga, and Northwest provinces), South
Korea (National Masan Tuberculosis Hospital, Masan, and Korean Institute of Tuberculosis,
Seoul), Thailand (Sakon Nakon, Srisaket, Ubon Ratchathani, and Yasothon provinces), and
Taiwan (nationwide). Inclusion criteria for the study were (1) pulmonary MDR TB confirmed
microbiologically by a local reference laboratory from a specimen collected within 30 d of start-
ing treatment and (2) receipt of second-line drugs for at least 30 d. South Africa restricted
enrollment to patients who had not previously been treated for MDR TB. Standardized infor-
mation was recorded at all sites, including demographic, socioeconomic, and clinical informa-
tion for each participant, and treatment and laboratory monitoring details.
Culture was performed on a baseline sputum sample, and monthly follow-up sputum sam-
ples were collected for the duration of treatment. Local laboratories performed cultures for
monitoring and DST for determining patient eligibility. A subset of isolates from patients
enrolled in the study were shipped in batches to CDC for centralized DST and genotyping.
Patients were eligible for inclusion in this analysis if they had positive cultures at the start of
treatment for MDR TB, if they had DST results from CDC for fluoroquinolones (DST was per-
formed for ciprofloxacin and ofloxacin) and second-line injectable drugs (i.e., amikacin,
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kanamycin, capreomycin), and if resistance to both isoniazid and rifampin were confirmed at
CDC. We excluded patients for whom the DST performed at CDC indicated susceptibility to
either isoniazid or rifampin in response to a reviewer suggestion, as several of these patients
were treated with isoniazid or rifampin. Patients with extensively drug-resistant tuberculosis
(XDR TB), defined as MDR TB with additional resistance to any fluoroquinolone and at least
one second-line injectable drug, were excluded from the analysis, as were patients for whom a
date of culture conversion or censoring could not be determined.
The primary research objective of PETTS was to determine whether the Green Light Com-
mittee approval process was associated with reduced amplification of drug resistance; the
results of this analysis have been previously reported [7]. However, the study protocol was con-
ceived to produce a dataset that could be used to answer several additional research questions
that required rigorous microbiological follow-up of MDR TB patients. The present analysis
was not contained in the original analysis plan, but was conceived because several recent publi-
cations suggested that regimens based on known drug susceptibilities and regimens containing
more drugs were associated with better clinical outcomes [2–5].
Definitions
Initial sputum culture conversion was defined as at least two consecutive negative cultures of
sputum samples collected at least 30 d apart. Time to sputum culture conversion was defined
as the time in days from the start of MDR TB treatment to the sputum specimen collection
date of the first of the consecutive negative cultures. Patients for whom sputum culture conver-
sion did not occur were censored 1 mo before the collection date of the last sputum specimen
because they were still at risk to convert during the last month of follow-up.
Classification of each drug’s effectiveness was based on the results of DST performed at CDC
on the baseline culture using the indirect agar plate proportion method [6]. DST was performed
for isoniazid, rifampin, ethambutol, ciprofloxacin, ofloxacin, amikacin, capreomycin, kanamycin,
streptomycin, rifabutin, ethionamide, and para-aminosalicylic acid. Drugs for which DST indi-
cated susceptibility were considered effective. Drugs for which the baseline DST result indicated
resistance were considered ineffective. In addition, levofloxacin and moxifloxacin were consid-
ered effective if no resistance to ciprofloxacin or ofloxacin was observed, and were considered
ineffective if resistance to either ciprofloxacin or ofloxacin was observed. Prothionamide was
considered effective if no resistance to ethionamide was observed, and ineffective if resistance to
ethionamide was observed. Drugs for which DST was not performed at CDC (cycloserine, terizi-
done, amoxicillin/clavulanate, clarithromycin, thioacetazone, clofazimine, imipenem, and linezo-
lid) were classified as untested drugs. Pyrazinamide, although not tested routinely, was kept
separate from this group of untested drugs because it is a first-line drug with a well-established
role in treatment, and it is recommended for routine inclusion in MDR TB regimens [1].
For each individual drug, we calculated the number of days during which the drug was
included in a patient’s regimen between initiation of MDR TB treatment and sputum culture
conversion or censoring. The number of days a drug was included in a patient’s regimen was
inferred from the dates the drug was started and stopped; if a single drug was started and
stopped multiple times, the days between each pair of start and stop dates were summed.
Drug-days were summed for all the drugs in each of four groups: effective drugs, ineffective
drugs, pyrazinamide, and untested drugs. For each group, this sum was divided by the number
of days before sputum culture conversion or censoring to calculate the average number of
drugs in each group that the patient received per day. In addition, a composite variable was cre-
ated to reflect the total number of “potentially effective drugs” received per day, which included
all effective drugs, pyrazinamide, and untested drugs.
MDR TB Regimen and Treatment Response
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Data Analysis
We analyzed the association between variables of interest and sputum culture conversion using
Cox proportional hazards regression. We stratified by country to control for setting-associated
confounders. We evaluated proportional hazards assumptions by testing the significance of
time-dependent interaction terms for all variables. We were interested in the associations
between time to sputum culture conversion and both the number of drugs in a regimen and
the presumed effectiveness of these drugs. Therefore, we generated two multivariable models
to assess the association between treatment regimen and time to sputum culture conversion. In
the first model, the exposure of interest was the average number of potentially effective drugs
received per day, analyzed as a categorical variable. In the second model, the exposures of inter-
est were the average numbers of drugs received in each of the four drug groups, analyzed as
continuous variables. We considered clinical and demographic covariates for inclusion in the
multivariable models based on the strength of univariate associations with sputum culture con-
version (covariates with Wald p< 0.1 were eligible for inclusion) or biological plausibility. The
resistance pattern at baseline and the number of drugs to which the baseline isolate was resis-
tant were retained in both models because of an established association between the extent of
baseline drug resistance and treatment success [8] and because the extent of drug resistance
was likely to be associated with resistance to untested drugs. To generate the final models, we
used backward elimination, assessing the effect of each elimination on the point estimates and
confidence intervals to identify potential confounders.
In the second model, we believed interactions among the different drug groups to be likely.
Therefore, we assessed both the main effects model and a model in which we considered all
two-way interactions among drug group variables. Collinearity among variables was assessed; a
variance inflation factor> 5 or a maximum condition index> 50 were considered evidence of
collinearity. As a sensitivity analysis, we restricted the first model to patients who did not
receive any Group 4 (oral second-line drugs other than fluoroquinolones) or Group 5 drugs
(drugs with antimycobacterial activity but unproven efficacy against drug-resistant TB) [1] for
which drug sensitivity was unknown. All analyses were performed using SAS 9.3.
Results
Out of 1,659 patients in the PETTS cohort, 1,137 were included in our analysis (Fig 1). These
patients were followed for a median of 20 mo (interquartile range 16–23 mo) after MDR TB
treatment initiation. Initial sputum culture conversion occurred for 909 (79.9%) patients at a
median of 2 mo (interquartile range 1–3 mo). However, the percentage of patients achieving
initial sputum culture conversion within 6 mo varied considerably by country (Table 1).
Time to initial sputum culture conversion among all patients by average number of poten-
tially effective drugs received per day is show graphically in Fig 2. As baseline drug resistance
pattern, drug exposure, and percentage of patients achieving initial sputum culture conversion
by 6 mo varied by country (Table 1), we stratified the statistical analysis by country to control
for setting-associated confounders. In stratified univariate analysis, receiving an average of at
least six potentially effective drugs per day was associated with a 34% increase in the likelihood
of sputum culture conversion compared to receiving an average of at least five but fewer than
six potentially effective drugs per day (hazard ratio [HR] 1.34 per effective drug, 95% CI 1.08–
1.65) (Table 2). In contrast, receiving fewer potentially effective drugs was associated with
lower likelihoods of sputum culture conversion (HR for fewer than four drugs 0.37, 95% CI
0.30–0.45; HR for at least four but fewer than five drugs 0.58, 95% CI 0.49–0.68).
In univariate analysis, stratified by country, the presence of more effective drugs in the regi-
men was associated with an increased likelihood of sputum culture conversion (HR 1.45 per
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effective drug, 95% CI 1.34–1.56), and inclusion of pyrazinamide in the regimen was associated
with a doubled likelihood of sputum culture conversion (HR 1.94, 95% CI 1.62–2.32) (Table 2).
In contrast, the presence of more untested drugs in the regimen was associated with a slightly
but significantly decreased likelihood of sputum culture conversion (HR 0.84 per untested
drug, 95% CI 0.73–0.96). The following were all associated with a lower likelihood of sputum
culture conversion: baseline resistance to more drugs (HR 0.87, 95% CI 0.83–0.92, per drug),
baseline resistance specifically to fluoroquinolones (HR 0.44, 95% CI 0.32–0.60) or second-line
injectable drugs (HR 0.58, 95% CI 0.45–0.74), hospitalization at enrollment (HR 0.68, 95% CI
0.51–0.91), previous treatment with second-line drugs (HR 0.56, 95% CI 0.42–0.74), positive
baseline sputum smear microscopy result (HR 0.73, 95% CI 0.57–0.94), radiographically deter-
mined bilateral disease (HR 0.72, 95% CI 0.61–0.85), and evidence of cavity formation (HR
0.83, 95% CI 0.72–0.95) (Table 2).
The results of the multivariable analyses are summarized in Table 3. In the first multivari-
able model, receiving an average of at least six potentially effective drugs per day was associated
with a 36% greater likelihood of sputum culture conversion than receiving an average of at
least five but fewer than six potentially effective drugs per day (adjusted hazard ratio [aHR]
1.36, 95% CI 1.09–1.69), after adjusting for extent and pattern of baseline resistance, previous
treatment history, sputum smear result, and extent of disease on chest radiograph. In contrast,
Fig 1. Inclusion of patients in the analysis.MDR-TB is tuberculosis resistant to at least isoniazid and
rifampin; XDR-TB is tuberculosis resistant to at least isoniazid, rifampin, one fluoroquinolone, and one
second-line injectable drug.
doi:10.1371/journal.pmed.1001932.g001
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Table 1. Baseline drug resistance and treatment characteristics of patients, by country (n = 1,137).
Characteristic Country







Number of patients included in
analysis
22 80 162 374 86 252 75 38 48
Site approved by Green Light
Committee
Yes Yes Yes Yes Yes No No No No
Number of drugs to which TB
resistant at baseline*
5 (3–8) 5 (2–10) 4 (2–9) 5 (2–8) 5 (2–9) 4 (2–10) 4 (2–9) 3 (2–7) 4 (2–8)
Resistance pattern at baseline†
MDR only 13 (59%) 41 (51%) 135 (83%) 348 (93%) 56 (65%) 195 (77%) 53 (71%) 30 (79%) 43 (90%)
MDR with resistance to any
second-line injectable
6 (27%) 34 (43%) 22 (14%) 5 (1%) 22 (26%) 51 (20%) 7 (9%) 1 (3%) 2 (4%)
MDR with resistance to any
fluoroquinolone
3 (14%) 5 (6%) 5 (3%) 21 (6%) 8 (9%) 6 (2%) 15 (20%) 7 (18%) 3 (6%)
Previous treatment history†
None 16 (73%) 45 (56%) 24 (15%) 0 (0%) 31 (36%) 9 (4%) 9 (12%) 22 (58%) 2 (4%)
First-line drugs only 2 (9%) 20 (25%) 111 (69%) 330 (88%) 33 (38%) 235 (93%) 28 (37%) 15 (39%) 42 (88%)
Second-line drugs 4 (18%) 14 (18%) 18 (11%) 44 (12%) 18 (21%) 8 (3%) 33 (44%) 1 (3%) 4 (8%)
Unknown 0 (0%) 1 (1%) 9 (6%) 0 (0%) 4 (5%) 0 (0%) 5 (7%) 0 (0%) 0 (0%)
Average number of potentially
effective drugs received per
day†
0 to <4 1 (5%) 13 (16%) 4 (2%) 76 (20%) 29 (34%) 102 (40%) 17 (23%) 6 (16%) 16 (33%)
4 to <5 4 (18%) 27 (34%) 12 (7%) 144 (39%) 35 (41%) 86 (34%) 22 (29%) 12 (32%) 18 (38%)
5 to <6 10 (45%) 29 (36%) 47 (29%) 130 (35%) 22 (26%) 55 (22%) 21 (28%) 15 (39%) 13 (27%)
6 or more 7 (32%) 11 (14%) 99 (61%) 24 (6%) 0 (0%) 9 (4%) 15 (20%) 5 (13%) 1 (2%)
Patients with initial sputum
culture conversion within 6 mo,
by average number of
potentially effective drugs
received‡
0 to <4 0 (0%) 7 (54%) 2 (50%) 70 (92%) 22 (76%) 21 (21%) 6 (35%) 5 (83%) 11 (69%)
4 to <5 1 (25%) 24 (89%) 4 (33%) 138 (96%) 26 (74%) 44 (51%) 7 (32%) 10 (83%) 12 (67%)
5 to <6 6 (60%) 27 (93%) 28 (59%) 128 (98%) 19 (86%) 44 (80%) 12 (57%) 15 (100%) 13 (100%)
6 or more 7 (100%) 7 (64%) 81 (82%) 23 (96%) N/A 9 (100%) 12 (80%) 5 (100%) 1 (100%)
Patients with initial sputum
culture conversion within 12
mo, by average number of
potentially effective drugs
received‡
0 to <4 0 (0%) 7 (54%) 2 (50%) 71 (93%) 23 (79%) 28 (27%) 7 (41%) 5 (83%) 13 (81%)
4 to <5 1 (25%) 24 (89%) 7 (58%) 139 (97%) 29 (83%) 50 (58%) 8 (36%) 11 (92%) 13 (72%)
5 to <6 6 (60%) 27 (93%) 32 (68%) 128 (98%) 19 (86%) 48 (87%) 12 (57%) 15 (100%) 13 (100%)
6 or more 7 (100%) 7 (64%) 86 (87%) 23 (96%) N/A 9 (100%) 12 (80%) 5 (100%) 1 (100%)
Initial sputum culture conversion was defined as at least two consecutive negative cultures of sputum samples collected at least 30 d apart.
*Median (range) presented.
†Number (column percent) presented.
‡Number (percent of those who received that number of drugs) presented.
MDR, multidrug resistant; N/A, not applicable.
doi:10.1371/journal.pmed.1001932.t001
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receiving fewer potentially effective drugs was associated with lower likelihoods of sputum cul-
ture conversion (aHR for fewer than four drugs 0.36, 95% CI 0.29–0.44; aHR for at least four
but fewer than five drugs 0.56, 95% CI 0.47–0.66). Similar results were observed when we
excluded from analysis 697 patients who received any Group 4 or 5 drug for which drug sus-
ceptibility was unknown (S1 Table).
In the second multivariable model, HRs associated with each drug group exposure of inter-
est were adjusted for the other drug group exposures, as well as for extent and pattern of base-
line resistance, previous treatment history, sputum smear result, and extent of disease on chest
radiograph. The main effects model produced similar estimates as the model that considered
interaction terms; therefore, we present the model that included the interaction terms, as sig-
nificant interactions were detected among effective drugs, untested drugs, and pyrazinamide.
For patients receiving one untested drug (the median number of untested drugs received), the
presence of one additional effective drug in the regimen was associated with a 65% greater like-
lihood of sputum culture conversion (aHR 1.65, 95% CI 1.48–1.84), and including pyrazina-
mide in the regimen was associated with a doubled likelihood of sputum culture conversion
(aHR 2.00, 95% CI 1.65–2.41). The presence of an additional ineffective drug in a regimen was
associated with a 33% greater likelihood of sputum culture conversion (aHR 1.33, 95% CI
1.18–1.51), despite resistance to ineffective drugs on baseline DST (Table 3).
The benefit of including untested drugs was dependent on the other drugs present in the
regimen (Table 4). For patients receiving two or fewer effective drugs, the presence of an addi-
tional untested drug was not associated with any significant acceleration of sputum culture
conversion. For patients receiving three effective drugs (the median number of effective drugs
received) and no pyrazinamide, the presence of an additional untested drug was associated
with a 39% greater likelihood of sputum culture conversion (aHR 1.39, 95% CI 1.09–1.76).
However, for patients receiving three effective drugs as well as pyrazinamide, the presence of
an additional untested drug was not associated with any significant increase in the likelihood
of sputum culture conversion (aHR 0.93, 95% CI 0.77–1.11). Additional results relating to
these interactions are included in S2 and S3 Tables. Drug exposures included in the untested
Fig 2. Time to initial sputum culture conversion by average number of potentially effective drugs received per day. Initial sputum culture conversion
was defined as at least two consecutive negative cultures of sputum samples collected at least 30 d apart.
doi:10.1371/journal.pmed.1001932.g002
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Table 2. Patient characteristics and univariate associations with sputum culture conversion among
patients treated for MDR TB (n = 1,137).
Predictor n (Percent) or Median
(Range)
HR (95% CI)
Average number of potentially effective drugs
received per day
0 to <4 264 (23%) 0.37 (0.30–0.45)
4 to <5 360 (32%) 0.58 (0.49–0.68)
5 to <6 342 (30%) Reference
6 or more 171 (15%) 1.34 (1.08–1.65)
Average number of effective drugs received per
day
3 (0–6.0) 1.45 (1.34–1.56) per
drug
Average number of ineffective drugs received per
day
0.6 (0–4.5) 0.94 (0.86–1.03) per
drug
Average doses of pyrazinamide received per day 1 (0–1.0) 1.94 (1.62–2.32) per
dose
Average number of untested drugs received per
day
1 (0–4.0) 0.84 (0.73–0.96) per
drug
Number of drugs to which TB resistant at baseline 4 (2–10) 0.87 (0.83–0.92) per
drug
Resistance pattern at baseline
MDR only 914 (80%) Reference
MDR with resistance to any second-line injectable 150 (13%) 0.58 (0.45–0.74)
MDR with resistance to any fluoroquinolone 73 (6%) 0.44 (0.32–0.60)
Hospitalized at enrollment
No 617 (54%) Reference
Yes 520 (45%) 0.68 (0.51–0.91)
Previous treatment history
None 158 (14%) Reference
First-line drugs only 816 (72%) 0.84 (0.66–1.06)
Second-line drugs 144 (13%) 0.56 (0.42–0.74)
Unknown 19 (2%) 0.49 (0.26–0.93)
Smear result
Negative 102 (9%) Reference
Positive 999 (88%) 0.73 (0.57–0.94)
Unknown 36 (3%) 0.22 (0.11–0.44)
Extent of disease on chest radiograph
Unilateral 215 (19%) Reference
Bilateral 901 (79%) 0.72 (0.61–0.85)
Unknown 21 (2%) 1.50 (0.93–2.42)
Site of disease
Pulmonary only 1,087 (96%) Reference
Pulmonary and extrapulmonary 49 (4%) 0.96 (0.70–1.32)
Evidence of cavity on chest radiograph
No 424 (37%) Reference
Yes 690 (61%) 0.83 (0.72–0.95)
Unknown 23 (2%) 1.20 (0.75–1.92)
HIV status
Negative 542 (48%) Reference
Positive 145 (13%) 0.94 (0.71–1.26)
Unknown 450 (40%) 1.55 (1.10–2.17)
(Continued)
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drug group were predominantly cycloserine and terizidone (47% and 25% of drug-days of
exposure, respectively), with Group 5 drugs comprising the remainder (a cumulative 28% of
drug-days of exposure). Neither bedaquiline nor delamanid, nor any experimental drugs, were
used in this cohort.
Independent associations between clinical covariates and sputum culture conversion were
similar in both multivariable models (Table 3). Compared to MDR TB with susceptibility to
both second-line injectable drugs and fluoroquinolones, MDR TB with added resistance to any
second-line injectable drug (model 1, aHR 0.51, 95% CI 0.38–0.70; model 2, aHR 0.56, 95% CI
0.42–0.76) and MDR TB with added resistance to any fluoroquinolone (model 1, aHR 0.52, 95%
CI 0.36–0.73; model 2, aHR 0.48, 95% CI 0.34–0.68) were associated with a lower likelihood of
sputum culture conversion. The following were independently associated with a decreased like-
lihood of sputum culture conversion: prior treatment with second-line tuberculosis drugs
(model 1, aHR 0.62, 95% CI 0.46–0.83; model 2, aHR 0.72, 95% CI 0.54–0.97), positive sputum
smear (model 1, aHR 0.72, 95% CI 0.56–0.92; model 2, aHR 0.73, 95% CI 0.56–0.94), and bilat-
eral disease (model 1, aHR 0.70, 95% CI 0.59–0.83; model 2, aHR 0.68, 95% CI 0.57–0.80). No
collinearity was observed among variables included in the multivariable models.
Discussion
In our analysis, greater numbers of potentially effective drugs in an MDR TB treatment regimen
were associated with accelerated sputum culture conversion. In general, inclusion of pyrazina-
mide or additional drugs to which baseline DST indicated susceptibility (i.e., effective drugs)
were associated with greater increases in the likelihood of sputum culture conversion than inclu-
sion of drugs to which baseline DST indicated resistance (i.e., ineffective drugs). The presence of
untested drugs in the regimen was associated with an increased likelihood of sputum culture con-
version only if a minimum number of effective drugs was present in the regimen.
Table 2. (Continued)




No 978 (86%) Reference
Yes 154 (14%) 1.02 (0.85–1.24)
Age (in years) 36 (18–81) 0.95 (0.90–1.01) per
10 y
Alcohol abuse
No 928 (82%) Reference
Yes 167 (15%) 0.85 (0.68–1.07)
Unknown 43 (4%) 0.59 (0.35–0.99)
Smokes tobacco
No 872 (77%) Reference
Yes 252 (22%) 0.83 (0.65–1.04)
Unknown 13 (1%) 0.71 (0.29–1.71)
HRs result from univariate Cox proportional hazards regression analysis for each variable, stratified by
country, with time to initial sputum culture conversion as the outcome. Initial sputum culture conversion was
defined as at least two consecutive negative cultures of sputum samples collected at least 30 d apart. HRs
in bold are statistically significant.
MDR, multidrug resistant.
doi:10.1371/journal.pmed.1001932.t002
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Table 3. Multivariable models for the association between regimen composition and sputum culture
conversion.
Predictor aHR (95% CI)
Model 1 Model 2
Average number of potentially effective
drugs received per day
Not included in model
0 to <4 0.36 (0.29–0.44)
4 to <5 0.56 (0.47–0.66)
5 to <6 Reference
6 or more 1.36 (1.09–1.69)




1.65 (1.48–1.84) per drug, when regimen
contains one untested drug




1.33 (1.18–1.51) per drug




2.00 (1.65–2.41) per drug, when regimen
contains one untested drug





Number of drugs to which TB resistant
at baseline*
1.09 (1.02–1.17) 1.07 (0.99–1.16) per drug
Resistance pattern at baseline
MDR only Reference Reference
MDR with resistance to any second-line
injectable
0.51 (0.38–0.70) 0.56 (0.42–0.76)
MDR with resistance to any fluoroquinolone 0.52 (0.36–0.73) 0.48 (0.34–0.68)
Previous treatment history
None Reference Reference
First-line drugs only 0.84 (0.66–1.06) 0.84 (0.67–1.07)
Second-line drugs 0.62 (0.46–0.83) 0.72 (0.54–0.97)
Unknown 0.46 (0.24–0.87) 0.53 (0.28–1.02)
Smear result
Negative Reference Reference
Positive 0.72 (0.56–0.92) 0.73 (0.56–0.94)
Unknown 0.25 (0.12–0.50) 0.22 (0.10–0.46)
Extent of disease on chest radiograph
Unilateral Reference Reference
Bilateral 0.70 (0.59–0.83) 0.68 (0.57–0.80)
Unknown 1.16 (0.71–1.87) 1.09 (0.67–1.78)
aHRs result from two separate Cox proportional hazards regression models for the association between
regimen composition and time to initial sputum culture conversion. All variables included in each model are
shown, and analysis was stratified by country. Model 1 characterizes regimens using the average number
of potentially effective drugs received, treated as a categorical variable. Model 2 characterizes regimens
using the average number of drugs in each of four categories, treated as continuous variables. Model 2
included the following two interaction terms: average number of effective drugs received per day × average
number of untested drugs received per day; average doses of pyrazinamide received per day × average
number of untested drugs received per day. Initial sputum culture conversion was defined as at least two
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We observed a benefit to receiving a greater number of potentially effective drugs (i.e., drugs
without a DST result indicating resistance), as well as an interaction in which the presence of
more effective drugs enhanced the benefit of untested drugs. Both of these results add to exist-
ing evidence that increasing the number of drugs in MDR TB regimens is advantageous.
Patients receiving individualized regimens containing a minimum of five probably effective
drugs for prolonged periods after sputum culture conversion have been shown to have
decreased risks of treatment failure, death, and relapse compared to patients receiving fewer
drugs [3–5]. In addition, high cure rates have been reported with only 9 mo of treatment using
a standardized regimen including seven drugs during the intensive phase [9]. In response to
the accumulating evidence for the benefit of increasing the number of drugs in regimens for
MDR TB, WHO guidelines for MDR TB regimen composition increased the minimum num-
ber of drugs recommended from four in 2006 and 2008 to five in 2011 [1,10]. Our results sug-
gest that treatment might be further fortified by adding additional potentially effective drugs.
In our analysis, for most patients, the increased likelihood of sputum culture conversion
associated with the presence of an additional effective drug in the regimen was greater than the
acceleration associated with the presence of an additional ineffective drug. This result suggests
that tailoring regimens based on DST results could improve treatment response. However, we
also observed a strong benefit to inclusion of pyrazinamide despite unknown efficacy, which
would appear to support the WHO recommendation to include pyrazinamide in MDR TB reg-
imens [1] without relying on DST results, which are known to be unreliable for this drug [11].
But as there were no DST results for pyrazinamide in this cohort, caution must be taken when
interpreting this finding. It is possible that clinicians accurately assessed the likelihood that pyr-
azinamide would be effective before deciding to use it, that the prevalence of pyrazinamide
resistance in the analyzed cohort was relatively low, or that the efficacy of pyrazinamide in
those patients with pyrazinamide susceptibility was so great that an association was observed
even though the drug was ineffective in a proportion of the patients who received it. In situa-
tions where undetected resistance renders pyrazinamide ineffective, a five-drug regimen that
Table 4. Multivariable model 2 adjusted hazard ratios for sputum culture conversion associated with
inclusion of one additional untested drug in the regimen, stratified by average number of effective
drugs received per day and inclusion of pyrazinamide in the regimen.
Average Number of Effective Drugs Received per Day* Pyrazinamide Included in Regimen
No Yes
0 0.78 (0.51–1.17) 0.52 (0.34–0.79)
1 0.94 (0.69–1.29) 0.63 (0.46–0.86)
2 1.14 (0.89–1.47) 0.76 (0.61–0.96)
3 1.39 (1.09–1.76) 0.93 (0.77–1.11)
4 1.68 (1.27–2.23) 1.13 (0.91–1.40)
5 2.04 (1.42–2.94) 1.37 (1.01–1.85)
6 2.48 (1.56–3.95) 1.66 (1.10–2.49)
Data presented are aHRs (95% CIs). aHRs are adjusted for average number of ineffective drugs received
per day, average number of untested drugs received per day, extent and pattern of baseline resistance,
previous treatment history, sputum smear result, and extent of disease. Analysis was stratified by country.
Initial sputum culture conversion was defined as at least two consecutive negative cultures of sputum
samples collected at least 30 days apart. 95% confidence intervals given in parentheses. aHRs in bold are
statistically significant.
*Median: 3; range: 0–6.
doi:10.1371/journal.pmed.1001932.t004
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includes pyrazinamide would actually contain only four effective drugs, which could put
patients at risk for poorer outcomes [12].
The drugs classified in our analysis as untested drugs comprise those classified as Group 5
by WHO [10], as well as the second-line drugs cycloserine and terizidone. Cycloserine was not
tested at CDC because testing requires Lowenstein–Jensen medium, and CDC performs DST
using Middlebrook medium or BACTEC broth medium. Because of inconclusive evidence
about the efficacy of Group 5 drugs, WHO recommends that they be used only to supplement
regimens if additional drugs are required [1]. Consistent with their supplementary role, we
observed that the benefit of including untested drugs was dependent on the other drugs present
in the regimen. Without a minimum number of effective drugs present, inclusion of an addi-
tional untested drug was not associated with any significant increase in the likelihood of spu-
tum culture conversion. Thus, our results suggest that it would be preferential to use the new
drugs bedaquiline and delamanid—which are almost certainly likely to be effective because of
their novel mechanisms and lack of prior use—in place of Group 5 drugs in treatment
regimens.
Unexpectedly, we observed that the addition of ineffective drugs was associated with a mod-
est but significant acceleration of sputum culture conversion. Possible explanations for this
observation include infection with multiple strains with differing drug susceptibilities, strains
with low-level resistance in vitro that were still susceptible in vivo to therapeutic drug concen-
trations, or synergistic effects between drugs. It is also possible that misclassification of drug
resistance occurred from our using ciprofloxacin and ofloxacin DST results to determine the
likely efficacy of moxifloxacin, as moxifloxacin susceptibility has been reported in approxi-
mately 30% of clinical isolates resistant to ofloxacin [13,14] or ciprofloxacin [14]. However, in
our study population, only 31 (2.7%) patients received moxifloxacin and had it classified as
ineffective based on resistance to ofloxacin or ciprofloxacin; therefore, the influence of this mis-
classification on our results as a whole was likely limited.
The associations with clinical covariates that we observed are consistent with previous stud-
ies involving patients with MDR TB that have shown associations between decreased likelihood
of sputum culture conversion and sputum smear positivity [15–17], bilateral extent of disease
[18], previous treatment with second-line drugs [16,18], and more extensive baseline drug
resistance [16,18].
Our analysis was subject to several important limitations. PETTS was an observational
study, not a randomized trial. In addition, while the study involved sites in nine different coun-
tries, our results may not be generalizable to other settings with very different MDR TB epi-
demics. For instance, the prevalence of pre–XDR TB fluoroquinolone resistance in the PETTS
cohort was substantially lower than has been reported among MDR TB patients in some South
Asian settings [19,20]. Choice of regimen varied across sites, as not all countries had all drugs
available. While we attempted to reduce bias by stratifying analysis by country and including
clinical covariates in our analysis, complete elimination of bias in a cohort of this diversity is
impossible. However, despite the limitations inherent to using observational data from treat-
ment programs, conclusions drawn from these data may in fact be more easily translatable to
clinical decision-making since they reflect results from ordinary practice.
A second set of limitations relates to assumptions made about drug efficacy. The range of
baseline resistance patterns and regimens received prevented us from assessing the effects of
individual drugs and from controlling for the varying efficacy of individual drugs. Thus, in our
analysis, the calculation of the average number of drugs received per day in a particular cate-
gory gave equal weight to all the drugs in that category even though, in reality, some drugs may
exert more of an effect than others. Furthermore, as we considered only baseline DST results
when determining drug effectiveness, our analysis did not take into account changing efficacy
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resulting from acquisition of drug resistance during treatment. However, we believe that rela-
tively few patients in our analytic cohort are likely to have acquired resistance prior to sputum
culture conversion or censoring, as only 68 PETTS patients acquired XDR TB during the
course of the study [7].
Our analysis was also limited by the data collected. Our quantification of drug exposure was
derived from the start and stop dates for individual drugs. However, the PETTS protocol speci-
fied that a stoppage need be recorded only if a drug was discontinued for at least 2 wk. There-
fore, our measures of drug exposure may be overestimates in some cases because brief
interruptions lasting less than 2 wk might not have been recorded. In addition, DST was not
performed for every drug that patients received, which prevented us from determining the
likely efficacy of all drugs included in the analysis. We also did not have adherence data corre-
sponding to each episode of drug prescription, and we assumed that prescription of a drug was
equivalent to its having been taken. This assumption was likely valid for Green Light Commit-
tee–approved programs, in which all treatment was administered under direct observation. If
adherence was poorer in countries without a Green Light Committee–approved program, we
would expect associations between drug exposure and sputum culture conversion to be attenu-
ated, biasing our results toward the null.
Finally, the interpretation of our results is limited by our use of time to initial sputum cul-
ture conversion as the outcome. We did not have long-term follow-up data to assess the risk of
relapse, nor did we consider sputum culture reversion (i.e., positive cultures obtained after ini-
tial sputum culture conversion) in our analysis. Time to initial sputum culture conversion is a
standard marker for treatment response in patients with tuberculosis, and has been shown to
correlate with treatment outcome in patients with MDR TB [18]. In the PETTS cohort, sputum
culture conversion at 6 mo was found to be a robust predictor of final treatment outcome [21].
However, our analysis could have been strengthened had we been able to assess the risk of
relapse as well, thereby allowing a comparison between the early prognostic marker of initial
sputum culture conversion and long-term treatment efficacy.
In conclusion, our analysis suggests that MDR TB regimens including more potentially
effective drugs than the minimum of five currently recommended by WHOmay encourage
improved response to treatment in patients with MDR TB. In addition, rapid access to high-
quality DST results could facilitate the design of more effective individualized regimens. How-
ever, randomized controlled trials are necessary to confirm whether individualized regimens
with more than five drugs can indeed achieve better cure rates than current recommended regi-
mens, and new rapid DST techniques will be required if knowledge of baseline drug resistance
is to guide regimen composition at the beginning of treatment.
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Editors' Summary
Background
Tuberculosis (TB)—a contagious bacterial disease that usually infects the lungs—is a global
public health problem. TheWorld Health Organization (WHO) estimates that, in 2014,
about 9.6 million people developed TB and 1.5 million people died from the disease.Myco-
bacterium tuberculosis, the organism that causes TB, is spread in airborne droplets when
people with TB cough. The symptoms of TB include persistent cough, fever, and weight loss;
diagnostic tests for TB include the culture (growth) ofM. tuberculosis from sputum samples
(mucus coughed up from the lungs) and chest X-rays. TB can be cured by taking several
antibiotics (including rifampicin and isoniazid) every day for six months. However, the
emergence of multidrug-resistant tuberculosis (MDR TB; TB with resistance to at least both
rifampicin and isoniazid) and extensively drug-resistant TB (MDR TB with additional resis-
tance to at least quinolones and to second-line injectable antibiotics) is now threatening TB
control efforts—about 5% of the cases of TB that occurred in 2014 were caused by MDR TB.
WhyWas This Study Done?
WHO guidelines for the treatment of MDR TB recommend a regimen that includes pyra-
zinamide and at least four second-line drugs (amikacin or other second-line injectable
drugs and fluoroquinolones such as ofloxacin) that are likely to be effective. When bacte-
rial drug susceptibility testing (DST) is not available, determination of the likely effective-
ness of drugs is based on patients’ previous exposure to antibiotics and the background
drug resistance levels in the community. Although the guidelines state that regimens based
on DST results are only marginally more effective than regimens determined without such
results, recent evidence suggests that DST results predict regimen effectiveness and that
regimens containing more drugs than currently recommended by the guidelines might be
beneficial. Here, the researchers undertake a prospective cohort study (an observational
study that compares outcomes in non-randomized groups of patients given different treat-
ments) to gain insights into how regimen design affects treatment response among people
with MDR TB. Specifically, the researchers analyze the association between both the num-
ber of potentially effective drugs included in a regimen and the DST results of the drugs in
the regimen and the time to sputum culture conversion (the time between treatment initia-
tion and having two consecutive negative sputum cultures).
What Did the Researchers Do and Find?
The researchers used a statistical approach called multivariable analysis to analyze data
(including baseline DST results and information on the time to sputum culture conver-
sion) collected from 1,137 adults with MDR TB who participated in the Preserving Effec-
tive Tuberculosis Treatment Study (PETTS). Receiving an average of at least six
potentially effective drugs per day (drugs without a baseline DST result indicating resis-
tance) was associated with a 36% greater likelihood of sputum culture conversion than
receiving an average of at least five but fewer than six potentially effective drugs per day.
Inclusion of more drugs to which baseline DST results indicated susceptibility was associ-
ated with a 65% higher likelihood of sputum culture conversion per drug, and inclusion of
pyrazinamide was associated with a doubling of the likelihood of sputum culture conver-
sion, Inclusion of more drugs to which baseline DST results indicated resistance was
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associated with only a 33% higher likelihood of sputum culture conversion per drug.
Finally, inclusion of more drugs for which DST had not been performed was beneficial
only if the regimen already contained a minimum of three likely effective drugs.
What Do These Findings Mean?
These findings suggest that regimens that include more potentially effective drugs than
currently recommended by WHOmight improve the response of patients with MDR TB
to treatment. In addition, these findings suggest that rapid access to high-quality DST
results could facilitate the design of more effective individualized regimens. However,
because this study was based on observational data, these findings do not prove that
increasing the number of drugs in treatment regimens or basing drug choice on DST
results improves outcomes. It is possible that all the patients who received a particular
treatment shared an unknown, non-drug-related characteristic that was actually responsi-
ble for their response to treatment. Additionally, the authors were not able to assess the
effects of individual drugs, and the analysis assumed equivalent efficacy for all drugs in a
particular category, which may not be true in reality. The authors also did not have data
on adherence or long-term follow-up to assess relapse or sputum culture reversion. Thus,
although these findings suggest that changes to the current WHO guidelines for the treat-
ment of MDR TB might be beneficial, randomized controlled trials should be undertaken
first to confirm whether individualized regimens that include more than five drugs can
achieve better cure rates than the currently recommended regimens.
Additional Information
This list of resources contains links that can be accessed when viewing the PDF on a device
or via the online version of the article at http://dx.doi.org/10.1371/journal.pmed.1001932.
• TheWorld Health Organization (WHO) provides information (in several languages) on
tuberculosis and on multidrug-resistant tuberculosis (in several languages); its
Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011
Update and the Global Tuberculosis Report 2015, which provides up-to-date information
about tuberculosis around the world, are available
• The Stop TB Partnership is working towards tuberculosis elimination and provides
personal stories about tuberculosis (in English and Spanish)
• The US Centers for Disease Control and Prevention provides information about
tuberculosis and about drug-resistant tuberculosis (in English and Spanish), including a
brief description of PETTS
• The US National Institute of Allergy and Infectious Diseases also has detailed informa-
tion on tuberculosis, including a drug-resistant tuberculosis visual tour
• TB &Me, a collaborative blogging project run by patients being treated for MDR TB
and Médecins Sans Frontières, provides more patient stories
• MedlinePlus has links to further information about tuberculosis (in English and Spanish)
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